Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282202 | 0.92 | DGAT1 (0.33) | DGAT1KCNH2AOC3 | |
| SCHEMBL1282403 | 0.89 | PTPN11 (0.36) | DGAT1KCNH2AOC3MAPT | |
| SCHEMBL1283705 | 0.89 | MEN1 (0.32) | MEN1KMT2ADGAT1KCNH2 | |
| SCHEMBL1282268 | 0.89 | DGAT1 (0.31) | DGAT1KCNH2 | |
| SCHEMBL1282904 | 0.88 | DGAT1 (0.33) | DGAT1KCNH2 | |
| SCHEMBL1282649 | 0.88 | AOC3 (0.31) | DGAT1KCNH2AOC3 | |
| SCHEMBL1282442 | 0.88 | DGAT1 (0.30) | DGAT1KCNH2 | |
| SCHEMBL17233339 | 0.88 | — | — | |
| SCHEMBL1282413 | 0.88 | GRM2 (0.31) | — | |
| SCHEMBL1283840 | 0.87 | CNR1 (0.33) | DGAT1KCNH2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | claimed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-3102203-A2 | ANTIBACTERIAL COMBINATIONS COMPRISING POLYMYXIN | SPERO GYRASE, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| WO-2015114452-A2 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2015-08-06 | — | — | WO | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | MEN1 3233/4885KMT2A 4333/4885POLB 815/4885 |
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | MEN1 4761/4885KMT2A 4497/4885POLB 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.